{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T14:53:02Z","timestamp":1774277582048,"version":"3.50.1"},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100012547","name":"Natural Science Foundation of Guangxi Zhuang Autonomous Region","doi-asserted-by":"publisher","award":["2022JJA140009"],"award-info":[{"award-number":["2022JJA140009"]}],"id":[{"id":"10.13039\/100012547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012547","name":"Natural Science Foundation of Guangxi Zhuang Autonomous Region","doi-asserted-by":"publisher","award":["2025GXNSFHA069049"],"award-info":[{"award-number":["2025GXNSFHA069049"]}],"id":[{"id":"10.13039\/100012547","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2026,3]]},"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n Systemic therapy combined with transcatheter arterial chemoembolization (TACE) is the main treatment strategy for patients with unresectable hepatocellular carcinoma (uHCC). Nevertheless, there are currently few direct comparative studies between different combined treatment regimens. Therefore, this study aims to compare the efficacy and safety of sintilimab and bevacizumab biosimilar (IBI305) versus PD\u20101 inhibitor and tyrosine kinase inhibitor (TKI) combined with TACE in the treatment of uHCC.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This retrospective study included 225 patients with uHCC who received either TACE combined with sintilimab and IBI305 (TSB group,\n n<\/jats:italic>\n \u2009=\u200984) or other PD\u20101 inhibitors and TKIs (TTP group,\n n<\/jats:italic>\n \u2009=\u2009141). This study evaluated overall survival (OS) as the primary outcome, with secondary endpoints encompassing progression\u2010free survival (PFS), objective response rate (ORR), disease control rate (DCR)and treatment\u2010related adverse events (TRAEs). To mitigate potential confounding biases across the two cohorts, propensity score matching (PSM) was employed.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Following PSM, 136 uHCC patients were included, with 68 in both the TSB and TTP groups. There was no statistical difference in OS (\n p<\/jats:italic>\n \u2009=\u20090.18) or PFS (\n p<\/jats:italic>\n \u2009=\u20090.34) between the TSB group and the TTP group. According to both RECIST1.1 and mRECIST criteria, there were no notable changes in ORR or DCR. Both groups demonstrated manageable toxicity profiles. Subgroup analysis suggested that whereas patients with large tumours (HR, 0.33;\n p<\/jats:italic>\n \u2009=\u20090.024), solitary lesions (HR, 0.16;\n p<\/jats:italic>\n \u2009<\u20090.001) or portal vein tumour thrombosis (HR, 0.43;\n p<\/jats:italic>\n \u2009=\u20090.033) derived greater survival benefit from the TSB regimen, those with multifocal tumours (HR, 1.86;\n p<\/jats:italic>\n \u2009=\u20090.033) benefited more from the TTP regimen.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The TSB and TTP regimens offer comparable efficacy and safety in uHCC, yet the TSB regimen appears to offer greater benefit in specific patient subgroups.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/liv.70551","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T12:56:53Z","timestamp":1771246613000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparing of Efficacy and Safety Between Sintilimab Plus\n IBI305<\/scp>\n and\n PD<\/scp>\n \u20101 Inhibitor Plus\n TKIs<\/scp>\n in Combination of\n TACE<\/scp>\n for\n uHCC<\/scp>"],"prefix":"10.1111","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9685-4401","authenticated-orcid":false,"given":"Houxiang","family":"Ya","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Pancreatic Surgery The First Affiliated Hospital of Guilin Medical University Guilin Guangxi Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatopancreatobiliary Surgery Affiliated Hospital Shenzhen Baoan Central Hospital of Guangdong Medical University Shenzhen Guangdong Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huixia","family":"Qin","sequence":"additional","affiliation":[{"name":"Interventional Centre The First Affiliated Hospital of Guilin Medical University Guilin Guangxi Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Pancreatic Surgery The First Affiliated Hospital of Guilin Medical University Guilin Guangxi Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hesheng","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Pancreatic Surgery The First Affiliated Hospital of Guilin Medical University Guilin Guangxi Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengyuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Pancreatic Surgery The First Affiliated Hospital of Guilin Medical University Guilin Guangxi Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiwen","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Pancreatic Surgery The First Affiliated Hospital of Guilin Medical University Guilin Guangxi Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Pancreatic Surgery The First Affiliated Hospital of Guilin Medical University Guilin Guangxi Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6930-6855","authenticated-orcid":false,"given":"Shuqun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Pancreatic Surgery The First Affiliated Hospital of Guilin Medical University Guilin Guangxi Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2024.102446"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1713263"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29913"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50047"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy308"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2023.0099"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31327"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12036-8"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(21)00252\u20107"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000530319"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392\u2010022\u201001235\u20100"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(24)02551\u20100"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(24)02575\u20103"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2008.10.004"},{"issue":"12","key":"e_1_2_12_17_1","first-page":"989","article-title":"Hepatocellular Carcinoma With Intra\u2010Atrial Tumour Growth: A Clinicopathologic Study of 18 Autopsy Cases","volume":"108","author":"Kojiro M.","year":"1984","journal-title":"Archives of Pathology and Laboratory Medicine"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.618206"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211002720"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102622"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S536381"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217851"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S404675"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S410967"},{"issue":"6","key":"e_1_2_12_25_1","first-page":"2540","article-title":"Lenvatinib Plus Sintilimab With or Without Transarterial Chemoembolization for Intermediate or Advanced Stage Hepatocellular Carcinoma: A Propensity Score\u2010Matching Cohort Study","volume":"13","author":"Lang M.","year":"2023","journal-title":"American Journal of Cancer Research"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v17.i1.96267"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v30.i43.4620"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35341"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575\u2010020\u201000395\u20100"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11423"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000776"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31840"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.01.021"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2559"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/2045\u2010824X\u20106\u201018"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.70551","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/liv.70551","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.70551","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T13:56:11Z","timestamp":1774274171000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.70551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/liv.70551"],"URL":"https:\/\/doi.org\/10.1111\/liv.70551","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"2025-11-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70551"}}